Skip to main content
. 2017 Aug 4;12(8):e0182646. doi: 10.1371/journal.pone.0182646

Fig 5. Anti-GM-CSF treatment leads to reduced mRNA expression of pro-inflammatory mediators at day 6 that are not observed with genetic GM-CSF deficiency.

Fig 5

(a) Il1b, Il6, Il17, Il22, Tnfa, and Il22ra1 mRNA levels relative to actin mRNA in IgG isotype-treated (n = at least 6) and anti-GM-CSF-treated (n = at least 7) wild-type mice; each symbol represents the quantified measured mRNA of one mouse. IMQPD was induced in mice by topical application of IMQ, and mRNA expression was analyzed in skin cells at day 6. (b) mRNA levels relative to actin mRNA in wild-type (Wt) and GM-CSF-/- mice (n = at least 7 for each). Symbols in graphs indicate mRNA levels in individual mice; horizontal bars show mean values ± SEM. *p-value<0.05, **p-value< 0.01, compared with control group as determined by the Mann-Whitney-U-Test.